뉴스

• Remedi Surges, HLB Hits Limit Down as FDA Blow Weighs[K-Bio Pulse] The Korean biotech sector saw sharply diverging performances on July 13, with newly listed Remedi. emerging as the day's standout performer, while HLB extended www.edaily.co.kr · 2026.07.14